Clinical trials
NSCLC, Stage I clinical trials
Below are recruiting nsclc, stage i clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07492342RecruitingPhase 2
Fulzerasib with immunotherapy and chemo before surgery for KRAS G12C lung cancer
This trial tests a combination of a targeted pill (Fulzerasib) and immunotherapy (Sintilimab) plus standard chemotherapy before surgery, for people with early-stage non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to shrink the tumor and make surgery more effective.
BeijingAges 18 years+ - NCT07167459Enrolling by invitationPhase 2
Personalized radiation for early stage lung cancer
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03872661RecruitingPhase 2
New lung cancer medicines before surgery for unresectable stage III
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
Guangzhou, GuangdongAges 18–75 - NCT06111807Recruiting
Validating blood tests for stage III lung cancer
This trial is testing whether new blood tests can reliably detect and monitor stage III non-small cell lung cancer (NSCLC). It hopes to improve how doctors track your cancer and decide on treatment.
Nice, NiceAges 18 years+ - NCT06671613Recruiting
Fasting-mimicking diet with immunotherapy for advanced lung cancer
This study combines a special periodic diet that mimics fasting with the standard immunotherapy drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer. The goal is to see if the diet can help the immunotherapy work better.
Long Beach, CaliforniaAges 18 years+ - NCT07016126RecruitingPhase 3
Study of D-BACE, chemo, and carlizumab for lung cancer
This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07609121RecruitingPhase 2
Radiation, Chemotherapy, and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07541521Recruiting
Robot-Assisted Lung Surgery After Immunotherapy for Lung Cancer
This trial tests whether combining immunotherapy with chemotherapy before robot-assisted lung surgery improves outcomes for patients with stage II–III non-small cell lung cancer. The goal is to shrink the tumor before surgery and then remove it completely using minimally invasive robotic techniques.
Fuzhou, FujianAges Any age - NCT06401824RecruitingPhase 2
Combination drug therapy for lung cancer with brain spread
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
AmsterdamAges 18 years+ - NCT06953843RecruitingPhase 2
Radiation and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05543330RecruitingPhase 1/Phase 2
M701 for lung cancer with pleural effusion
This trial tests a new drug called M701 for people with non-small cell lung cancer that has spread to the lining of the lung, causing fluid buildup (pleural effusion). It aims to see if M701 can help control the fluid and improve symptoms.
Hangzhou, ZhejiangAges 18–75 - NCT07120282RecruitingPhase 2
Tislelizumab after surgery for early-stage lung cancer
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
BeijingAges 18 years+ - NCT06501391RecruitingPhase 2
Brain radiation plus chemo-immunotherapy for untreated NSCLC with stable brain metastases
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
ShanghaiAges 18 years+ - NCT06501378RecruitingPhase 2
Brain radiation plus chemotherapy and immunotherapy for lung cancer brain metastases
This trial tests a combination of radiation to the brain plus chemotherapy and immunotherapy (anti-PD-1/PD-L1) for people with newly diagnosed non-small cell lung cancer that has spread to the brain. It is for those whose tumors do not have common driver mutations and whose brain metastases are causing symptoms.
ShanghaiAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT06234579Recruiting
Genetic changes in ALK-positive lung cancer over time
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
RomeAges 18 years+ - NCT06656598RecruitingPhase 2
Adjuvant treatment for elderly or unfit patients with stage III lung cancer
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy, followed by radiation, can help older or less fit patients with stage III lung cancer. The goal is to see if this combination improves outcomes compared to usual care.
AngersAges 18 years+ - NCT06563999RecruitingPhase 2
Study of new drugs for stage III lung cancer with rare gene changes
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
Guangzhou, GuangdongAges 18–75 - NCT06878274RecruitingPhase 2
Radiation after chemo-immunotherapy and surgery for stage III lung cancer
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
Montreal, QuebecAges 18 years+ - NCT07188480Recruiting
DNA and RNA testing for advanced lung cancer
This study tests a new way to analyze DNA and RNA from lung tumor samples taken during a bronchoscopy. It aims to find genetic changes that could help guide treatment for people with advanced non-small cell lung cancer.
Bologna, BolognaAges 18 years+ - NCT06634199Recruiting
Immune response after chemoradiation and immunotherapy for stage III lung cancer
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
Ferrol, A CoruñaAges 18 years+ - NCT07042724Recruiting
Exercise and nutrition for early-stage lung cancer
This study explores whether a personalized exercise and nutrition program can improve outcomes for people with early-stage NSCLC. If you qualify, you will receive support from a health team and use a device to monitor your progress.
VeronaAges 18 years+ - NCT05441566Enrolling by invitation
Checking MRD after surgery in early lung cancer
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
ShenzhenAges 18–100 - NCT06714708RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo before surgery for lung cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
Hefei, AnhuiAges 18 years+
Hear when a new NSCLC, Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nsclc, stage i?
- Yes. Clin2 currently lists 151 recruiting nsclc, stage i studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nsclc, stage i trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nsclc, stage i trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.